In addition, m6A-related signature has been identified as biomarker for tumor immune phenotypes and anti-PD-1 immunotherapy treatment response in lung adenocarcinoma (LADC) (72, 73), stomach adenocarcinomas (STADs) (74), Esophageal squamous cell carcinoma (ESCC) (75, 76), Renal Papillary Cell Carcinoma (RPCC), Hepatocellular Carcinoma (HCC) (77, 78). The gene discussed is PDCD1; the disease is neoplasm.